Identification of ZDHHC1 as a Pyroptosis Inducer and Potential Target in the Establishment of Pyroptosis-Related Signature in Localized Prostate Cancer.
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
08
2022
revised:
04
11
2022
accepted:
11
11
2022
entrez:
2
1
2023
pubmed:
3
1
2023
medline:
4
1
2023
Statut:
epublish
Résumé
Pyroptosis or cellular inflammatory necrosis is a programmed cell death kind. Accumulating evidence shows that pyroptosis plays a crucial role in the invasion, metastasis, and proliferation of tumor cells, thus affecting the prognosis of tumors and therapeutic effects. Prostate cancer (PCa), a common malignancy among men, is associated with inflammation. Pathophysiological effects of pyroptosis on tumor development and progression, as well as the mediation of PCa, are known, but its effects on the potential prognosis for PCa warrant in-depth investigation. Herein, we built a risk model of six pyroptosis-related genes and verified their predictive abilities for prognostic and therapeutic effects. Higher risk scores indicated a higher probability of biochemical recurrence (BCR), higher immune infiltration, and worsened clinicopathological features. To derive scientific and reliable predictions for BCR in patients having PCa, the findings of the current study were verified in the Gene Expression Omnibus (GEO) cohort following evaluation in The Cancer Genome Atlas (TCGA) dataset. Additionally, after evaluating the six genes in the model, ZDHHC1 was found to be an important component. Its antitumor role was further assessed through in vivo and in vitro experiments, and its promoting effect on pyroptosis was further evaluated and verified. The above results provided a new perspective for further studies on pyroptosis and its clinical utility for PCa.
Identifiants
pubmed: 36589680
doi: 10.1155/2022/5925817
pmc: PMC9800907
doi:
Substances chimiques
ZDHHC1 protein, human
EC 2.3.1.-
Acyltransferases
EC 2.3.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5925817Informations de copyright
Copyright © 2022 Cheng-Gong Luo et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cell Death Dis. 2019 Sep 9;10(9):650
pubmed: 31501419
Drug Discov Ther. 2013 Dec;7(6):233-42
pubmed: 24423654
Oncogene. 2020 Jun;39(24):4728-4740
pubmed: 32404986
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Atherosclerosis. 2021 Jan;317:1-9
pubmed: 33321327
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19
pubmed: 29905907
Clin Gastroenterol Hepatol. 2019 Apr;17(5):914-921.e5
pubmed: 29775793
Oxid Med Cell Longev. 2019 Oct 13;2019:8746895
pubmed: 31737176
Nature. 1992 Jul 9;358(6382):167-9
pubmed: 1614548
J Exp Med. 2018 Feb 5;215(2):699-718
pubmed: 29339449
Cold Spring Harb Perspect Biol. 2020 Mar 2;12(3):
pubmed: 31451512
J Exp Clin Cancer Res. 2021 May 03;40(1):153
pubmed: 33941231
Trends Microbiol. 2001 Mar;9(3):113-4
pubmed: 11303500
Pharmacol Res. 2021 Jan;163:105324
pubmed: 33276100
Nat Rev Cancer. 2019 Jan;19(1):46-59
pubmed: 30538273
Nature. 2017 Jul 6;547(7661):99-103
pubmed: 28459430
J Cell Mol Med. 2020 May;24(10):5797-5810
pubmed: 32281273
Onco Targets Ther. 2019 Dec 27;12:11475-11486
pubmed: 31920336
Front Oncol. 2019 Sep 26;9:971
pubmed: 31616642
J Immunol. 2017 Apr 15;198(8):3205-3213
pubmed: 28258192
Infect Immun. 1997 Dec;65(12):5165-70
pubmed: 9393811
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
J Proteome Res. 2020 Feb 7;19(2):644-654
pubmed: 31816243
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Trends Cell Biol. 2017 Sep;27(9):673-684
pubmed: 28619472
Oncogene. 2021 Sep;40(35):5416-5426
pubmed: 34282274
Nature. 2016 Jul 06;535(7610):153-8
pubmed: 27383986
Int J Gen Med. 2021 Sep 16;14:5675-5692
pubmed: 34557022
Front Cell Dev Biol. 2021 Dec 02;9:719390
pubmed: 34938729
Nat Rev Clin Oncol. 2020 Mar;17(3):168-182
pubmed: 31712648
Cell Host Microbe. 2014 Oct 8;16(4):450-61
pubmed: 25299331
Trends Biochem Sci. 2017 Apr;42(4):245-254
pubmed: 27932073
Trends Immunol. 2017 Apr;38(4):261-271
pubmed: 28196749
Science. 2020 Sep 18;369(6510):
pubmed: 32943500
Cell Cycle. 2008 Sep 15;7(18):2886-93
pubmed: 18787405
Chem Biol Interact. 2020 May 25;323:109052
pubmed: 32169591
Int J Cancer. 2013 Oct 1;133(7):1743-50
pubmed: 23504603
Lancet Oncol. 2014 Dec;15(13):1521-1532
pubmed: 25456371
Theranostics. 2020 Jul 25;10(21):9495-9511
pubmed: 32863941
Nat Commun. 2017 Jan 03;8:14128
pubmed: 28045099
Front Cell Dev Biol. 2021 Jun 11;9:676485
pubmed: 34179006
Eur Urol. 2015 Jun;67(6):1160-1167
pubmed: 25301759
Nucleic Acids Res. 2019 Jul 9;47(12):6160-6171
pubmed: 31066450
Genes Dev. 2016 Feb 15;30(4):399-407
pubmed: 26883359
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2396-401
pubmed: 10051653
Eur Urol. 2014 Aug;66(2):243-50
pubmed: 24680359
Cancer Manag Res. 2018 Dec 31;11:369-378
pubmed: 30643462